STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.
- Resource Type
- Article
- Source
Cell Cycle . Apr2022, Vol. 21 Issue 8, p767-779. 13p.- Subject
- Language
- ISSN
- 1538-4101